Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Redx Pharma Plc | Summit Therapeutics PLC | Netscientific PLC

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.


This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.


The event is not suitable for people pursuing commercial opportunities.


Netscientific PLC

RSS Portfolio


NetScientific's mission is to build a transatlantic biomedical and healthcare group funding and developing technologies that offer transformative benefits to people's lives and society.

NetScientific funds, develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe with a primary focus on Digital health, Diagnostics and Therapeutics. These represent highly attractive growth markets where breakthrough technology solutions are in high demand.

NetScientific is an active investor providing extensive management support. This can involve the senior management team initially taking leadership roles in companies and building dedicated management teams as the companies develop and grow.

Market: AIM
52-week High/Low: 84.60p / 49.23p
Market Cap: 25.79M

View full company profile

Redx Pharma Plc

RSS Portfolio


Redx Pharma is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high unmet medical need, in cancer, immunology and infection. By improving the characteristics of existing drug classes, we aim to create differentiated, novel drugs.

Redx has an established portfolio of proprietary drug programs that it is developing alone and in partnership with leading pharmaceutical companies and healthcare bodies. Two of our high value programs are advancing into Phase I clinical development for gastric, biliary and pancreatic cancers, and leukaemia. It is our aim that our discoveries will provide a pipeline of potential assets to complement and combine with the drug portfolios of larger and emerging pharmaceutical companies.

Market: AIM
52-week High/Low: 67.80p / 23.00p
Market Cap: 40.95M

View full company profile

Summit Therapeutics PLC

RSS Portfolio


We are seeking to treat all boys and young men afflicted with the fatal disease Duchenne muscular dystrophy with our pioneering utrophin modulation technology.

We are also advancing a highly selective novel antibiotic for C. difficile infection.

Market: AIM
52-week High/Low: 262.00p / 88.00p
Market Cap: 111.31M

View full company profile

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use